Impact of amino acid variations in gag and protease of HIV type 1 CRF01-AE strains on drug susceptibility of virus to protease inhibitors

Journal of Acquired Immune Deficiency Syndromes

Volumn 52, Issue 3, 2009, Pages 320-328

  Jinnopat, Piyamat ^a   Isarangkura Na Ayuthaya, Panasda ^b   Utachee, Piraporn ^a   Kitagawa, Yukiko ^b   De Silva, U Chandimal ^a,d   Siripanyaphinyo, Uamporn ^a,d   Kameoka, Yoko ^a   Tokunaga, Kenzo ^e   Sawanpanyalert, Pathom ^b   Ikuta, Kazuyoshi ^a,c   Auwanit, Wattana ^b   Kameoka, Masanori ^a,c  

^a Thailand Japan Research Collaboration Center on Emerging and Re emerging Infections RCC ERI   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c Departments of Virology   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

CRF01 AE; Drug resistance; Gag; Protease; Protease inhibitor

Indexed keywords

AMPRENAVIR; ATAZANAVIR; DARUNAVIR; GAG PROTEIN; INDINAVIR; ISOLEUCINE; LOPINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; VALINE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; THAILAND; VIRUS GENE; VIRUS RECOMBINANT; VIRUS RESISTANCE; VIRUS STRAIN;

AMINO ACID SEQUENCE; DRUG RESISTANCE, VIRAL; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION REGULATION, VIRAL; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; THAILAND;

EID: 70350536652     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181b4b18c     Document Type: Article

References (57)

1. Hemelaar J, Gouws E, Ghys PD, et al. Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. AIDS. 2006;20: W13-W23.
2. McCutchan FE. Global epidemiology of HIV. J Med Virol. 2006;78: S7-S12.
3. Gulick RM, Mellors JW, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337: 734-739.
4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725-733.
5. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
6. Birk M, Sönnerborg A. Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS. 1998;12:2369-2375.
7. Bon I, Gibellini D, Borderi M, et al. Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol. 2007;38:313-320.
8. Cane PA, de Ruiter A, Rice P, et al. Resistance-associated mutations in the human immunodeficiency virus type 1 subtype C protease gene from treated and untreated patients in the United Kingdom. J Clin Microbiol. 2001;39:2652-2654.
9. Fleury HJ, Toni T, Lan NTH, et al. Susceptibility to antiretroviral drugs of CRF01-AE, CRF02-AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data. AIDS Res Hum Retroviruses. 2006;22:357-366.
10. Handema R, Terunuma H, Kasolo F, et al. Prevalence of drug resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1. AIDS Res Hum Retroviruses. 2003;19:151-160.
11. Holgúin A, Paxinos E, Hertogs K, et al. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. J Clin Virol. 2004;31: 215-220.
12. Jenwitheesuk E, Watitpun C, Vibhagool A, et al. Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002. Ann Clin Microbiol Antimicrob. 2002;2:4.
13. Pieniazek D, Rayfield M, Hu DJ, et al. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. AIDS. 2000;14:1489-1495.
14. Sukasem C, Churdboonchart V, Sirisidthi K, et al. Genotypic resistance mutations in treatment-näive and treatment-experienced patients under widespread use of antiretroviral drugs in Thailand: implications for further epidemiologic surveillance. Jpn J Infect Dis. 2007;60:284-289.
15. Vergne L, Paraskevis D, Vandamme AM, et al. High prevalence of CRF02-AG and many minor resistance-related mutations at the protease gene among HIV-infected treatment-naive immigrants in Madrid. AIDS. 2003;17:1105-1107.
16. Vergne L, Peeters M, Mpoudi-Ngole E, et al. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol. 2000;38: 3919-3925.
17. Vergne L, Stuyver L, Van Houtte M, et al. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients. J Clin Virol. 2006;36:43-49.
18. Abecasis AB, Deforche K, Bacheler LT, et al. Investigation of baseline susceptibility to protease inhibitors in HIV-1 subtypes C, F, G and CRF02-AG. Antivir Ther. 2006;11:581-589.
19. Kinomoto M, Appiah-Opong R, Brandful JAM, et al. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors. Clin Infect Dis. 2005;41:243-251.
20. Velazquez-Campoy A, Todd MJ, Vega S, et al. Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes. Proc Natl Acad Sci U S A. 2001;98:6062-6067.
21. Bally F, Martinez R, Peters S, et al. Polymorphism of HIV type 1 Gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Hum Retroviruses. 2000;16: 1209-1213.
22. Barrie KA, Perez EE, Lamers SL, et al. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1. Virology. 1996;219:407-416.
23. de Oliveira T, Engelbrecht S, Janse van Rensburg E, et al. Variability at human immunodeficiency virus type 1 subtype C protease cleavage sites: an indication of viral fitness? J Virol. 2003;77:9422-9430.
24. Gallego O, de Mendoza C, Corral A, et al. Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. J Clin Microbiol. 2003;41:1245-1247.
25. Gilbert PB, Novitsky V, Essex M. Covariability of selected amino acid positions for HIV type 1 subtypes C and B. AIDS Res Hum Retroviruses. 2005;21:1016-1030.
26. Marlowe N, Flys T, Hackett J Jr, et al. Analysis of insertions and deletions in the gag p6 region of diverse HIV type 1 strains. AIDS Res Hum Retroviruses. 2004;20:1119-1125.
27. Carrillo A, Stewart KD, Sham HL, et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol. 1998; 72:7532-7541.
28. Côté HCF, Brumme ZL, Harrigan PR. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir. J Virol. 2001;75:589-594.
29. Doyon L, Croteau G, Thibeault D, et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol. 1996;70:3763-3769.
30. Gatanaga H, Suzuki Y, Tsang H, et al. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem. 2002;277:5952-5961.
31. Kaufmann GR, Suzuki K, Cunningham P, et al. Impact of HIV type 1 protease, reverse transcriptase, cleavage site, and p6 mutations on the virological response to quadruple therapy with saquinavir, ritonavir, and two nucleoside analogs. AIDS Res Hum Retroviruses. 2001;17: 487-497.
32. Maguire MF, Guinea R, Griffin P, et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol. 2002;76: 7398-7406.
33. Matsuoka-Aizawa S, Sato H, Hachiya A, et al. Isolation and molecular characterization of a nelfinavir (NFV)-resistant human immunodeficiency virus type 1 that exhibits NFV-dependent enhancement of replication. J Virol. 2003;77:318-327.
34. Myint L, Matsuda M, Matsuda Z, et al. Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2004;48:444-452.
35. Tamiya S, Mardy S, Kavlick MF, et al. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors. J Virol. 2004;78:12030-12040.
36. Zhang YM, Imamichi H, Imamichi T, et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol. 1997;71:6662-6670.
37. Nukoolkarn S, Pongthapisith V, Panyim S, et al. Sequence variability of the HIV type 1 protease gene in Thai patients experienced with antiretroviral therapy. AIDS Res Hum Retroviruses. 2004;20:1368-1372.
38. Adachi A, Gendelman HE, Koenig S, et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and non-human cells transfected with an infectious molecular clone. J Virol. 1986; 59:284-291.
39. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. Nucleic Acids Res. 1994;22:4673-4680.
40. Kitagawa Y, Kameoka M, Shoji-Kawata S, et al. Inhibitory function of adapter-related protein complex 2 alpha 1 subunit in the process of nuclear translocation of human immunodeficiency virus type 1 genome. Virology. 2008;373:171-180.
41. Fouchier RAM, Meyer BE, Simon JHM, et al. HIV-1 infection of non-dividing cells: evidence that the amino-terminal basic region of the viral matrix protein is important for Gag processing but not for post-entry nuclear import. EMBO J. 1997;16:4531-4539.
42. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16:62-68.
43. Doyon L, Tremblay S, Bourgon L, et al. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 2005;68:27-35.
44. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med. 1996;2: 760-766.
45. Partaledis JA, Yamaguchi K, Tisdale M, et al. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol. 1995;69:5228-5235.
46. Hodge CN, Aldrich PE, Bacheler LT, et al. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol. 1996;3:301-314.
47. Kaplan AH, Michael SF, Wehbie RS, et al. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci U S A. 1994;91:5597-5601.
48. Menzo S, Rusconi S, Monachetti A, et al. Quantitative evaluation of the recombinant HIV-1 phenotype to protease inhibitors by a single-step strategy. AIDS. 2000;14:1101-1110.
49. Petropoulos CJ, Parkin NT, Limoli KL, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000;44:920-928.
50. Bandaranayake RM, Prabu-Jeyabalan M, Kakizawa J, et al. Structural analysis of human immunodeficiency virus type 1 CRF01-AE protease in complex with the substrate p1-p6. J Virol. 2008;82:6762-6766.
51. Clemente JC, Coman RM, Thiaville MM, et al. Analysis of HIV-1 CRF-01 A/E protease inhibitor resistance: structural determinants for maintaining sensitivity and developing resistance to atazanavir. Biochemistry. 2006;45:5468-5477.
52. Weinheimer S, Discotto L, Friborg J, et al. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones. Antimicrob Agents Chemother. 2005;49:3816-3824.
53. De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother. 2005;49:2314-2321.
54. Koh Y, Nakata H, Maeda K, et al. Novel bis-tetrahydrofuranylurethane- containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 2003;47:3123-3129.
55. Larder BA, Hertogs K, Bloor S, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS. 2000;14:1943-1948.
56. Rusconi S, La Seta Catamancio S, Citterio P, et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother. 2000;44:1328-1332.
57. Gupta RK, Kohli A, McCormic A, et al. Evidence of full-length Gag as a determinant of susceptibility to protease inhibitors across HIV-1 subtype A, B, and C [633]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 9, 2009; Montreal, Canada.